How to Build CHD@ZJU

CHD related Articles were retrieved from Pubmed, by entering keywords "coronary heart disease" and constrict the publish date from 2000/1/1 to now (2013/1/23). As a result, totally 115898 articles were found and their abstracts were downloaded for text mining. Since some articles didn't contain abstracts, only 88396 abstracts remained.

The text-mining process to get CHD related genes could be divided in to 5 following steps:

  • 1) Extracting all keywords from abstracts and ignoring those keywords start with numbers. 101402 keywords were extracted.

  • 2) Input these keywords into Gene library in ArrayTrack and find possible related genes. 4674 genes were then found.

  • 3) Put these 4674 genes again into pubmed abstracts to find related aticles. Only genes which offical name or there keyword description (such as prolactin for gene PRL) could be found in the abstract would be remained. As a result, 1247 genes were remained.

  • 4) Manually examined on the 1247 genes to validate it was acutally related to CHD. Some genes would be filtered if it represents other meanings (such as gene CAD, Entrez ID:790, carbamoyl-phosphate synthetase 2, is mostly meant coronary arterial disease in articles). 681 genes were then validated with at least one reference.

  • 5) All genes was compared with 1078 CHD genes in RGD database, and 370 genes were overlapped. These 370 genes were labels as "RGD_Supported" and the other 293 genes were labels as "REFERED". All 663 genes had supported references in CHD@ZJU which were examined by step 4.
  • How To contact Us

    Collaboration Information: Prof. Xiaohui Fan (fanxh@zju.edu.cn)

    Website using assistance : Leihong Wu (11019004@zju.edu.cn)



    Basic Information

    Gene Name: CYP19A1

    Description: "cytochrome P450, family 19, subfamily A, polypeptide 1"

    Entrez Gene ID: 1588

    SwissProt Acc Number: P11511

    RefSeq: NM_000103

    It was suspected to be CHD related:

    .."CYP19A1 encodes aromatase, the enzyme responsible for the conversion of androgens to estrogens, and may play a role in variation in outcomes among men and women with cardiovascular disease.//this study is the first to document a significant interaction between CYP19A1 genotype and sex on cardiovascular outcomes."..

    From PMID: 21170323, in Journal PLoS One. , 2010


    References

    There were 1 potential papers with CYP19A1 and CHD.

    PMIDTitleJournalsDetails
    21170323 Aromatase gene polymorphisms are associated with survival among patients with cardiovascular disease in a sex-specific manner.PloS oneMore Details

    NOTEs: These result is mostly from TEXT-MINING and there might have mismatches.



    PPI interactions

    There were totally 1 unique genes interacted with CYP19A1. Show PPI network

    Gene nameInteraction typereference PMIDCHD relation
    FANCG in vitro11756225 No


    Involved FDA drugs

    StatusDrubBank IDNameIndicationATC Code
    approvedDB00357Aminoglutethimide"For the suppression of adrenal function in selected patients with Cushing's syndrome, malignant neoplasm of the female breast, and carcinoma in situ of the breast."L02BG01
    approvedDB00894TestolactoneFor palliative treatment of advanced breast cancer in postmenopausal women.
    approvedDB00990ExemestaneFor the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.L02BG06
    approvedDB01006LetrozoleFor the extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy. Also for first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer. Also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy.L02BG04
    approvedDB01217Anastrozole"For adjuvant treatment of hormone receptor positive breast cancer , as well as hormonal treatment of advanced breast cancer in post-menopausal women. Has also been used to treat pubertal gynecomastia and McCune-Albright syndrome; however, manufacturer states that efficacy for these indications have not been established."L02BG03